Promising radioactive treatment shows up to 75% response in tough childhood cancer
NCT ID NCT01163383
First seen Apr 19, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This expanded access program provides a radioactive drug called 131 I-MIBG to children (age 1 and older) with neuroblastoma that has not responded to standard treatments or has come back. The drug targets and kills cancer cells with radiation. Early results from a related study showed that adding another drug (vorinostat) led to a 75% response rate after two cycles, though this combination is not yet FDA-approved for neuroblastoma. The goal is to offer treatment while collecting more data on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
The Children's Hospital of Philadelphia
AVAILABLEPhiladelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.